Completed PHASE1 INTERVENTIONAL 4-arm NCT01327066

Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose

A Double-Blind Randomized Crossover Trial to Define the Ecg Effects of Droxidopa Using a Clinical and a Supratherapeutic Dose Compared With Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: a Thorough ECG Trial

Sponsor: Chelsea Therapeutics

Conditions QTc Interval

Interventions Droxidopa Moxifloxacin Placebo

Updated 6 times since 2017 Last updated: Mar 6, 2012 Started: Mar 31, 2011 Primary completion: Apr 30, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on QTc Interval, this trial is completed. The trial is conducted by Chelsea Therapeutics and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chelsea Therapeutics

Data source: Chelsea Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States